# Temperature-dependent regulation of mycolic acid cyclopropanation in saprophytic mycobacteria: Role of the Mycobacterium smegmatis 1351 gene (MSMEG-1351) in cis-cyclopropanation of α-mycolates

Laeticia Alibaud, Anuradha Alahari, Xavier Trivelli, Anil K. Ojha, Graham F. Hatfull, Yann Guerardel, Laurent Kremer

<figure><img src="image_1.png" /></figure>

## To cite this version:

Laeticia Alibaud, Anuradha Alahari, Xavier Trivelli, Anil K. Ojha, Graham F. Hatfull, et al.. Temperature-dependent regulation of mycolic acid cyclopropanation in saprophytic mycobacteria: Role of the Mycobacterium smegmatis 1351 gene (MSMEG-1351) in cis-cyclopropanation of α-mycolates. Journal of Biological Chemistry, 2010, 285 (28), pp.21698-21707. 10.1074/jbc.M110.125724. hal-00641584

HAL Id: hal-00641584

https://hal.science/hal-00641584v1

Submitted on 27 May 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
# Temperature-dependent Regulation of Mycolic Acid Cyclopropanation in Saprophytic Mycobacteria

## ROLE OF THE MYCOBACTERIUM SMEGMATIS 1351 GENE (MSMEG_1351) IN CIS-CYCLOPROPANATION OF α-MYCOLATES*§

Received for publication, March 23, 2010, and in revised form, May 3, 2010 Published, JBC Papers in Press, May 10, 2010, DOI 10.1074/jbc.M110.125724

Laeticia Alibaud†, Anuradha Alahari††, Xavier Trivelli§¶, Anil K. Ojha||, Graham F. Hatfull**, Yann Guerardel§¶, and Laurent Kremer‡‡‡+

From the ‡Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Université de Montpellier II et I, CNRS, UMR 5235, Case 107, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France, ‡‡INSERM, Dynamique des Interactions Membranaires Normales et Pathologiques, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France, §Université des Sciences et Technologies de Lille, Unité de Glycobiologie Structurale et Fonctionnelle, F-59650 Villeneuve d'Ascq, France, ¶CNRS, UMR 8576, F-59650 Villeneuve d'Ascq, France, the ‖Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, and the **Department of Biological Sciences and Pittsburgh Bacteriophage Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15260

The cell envelope is a crucial determinant of virulence and drug resistance in *Mycobacterium tuberculosis*. Several features of pathogenesis and immunomodulation of host responses are attributable to the structural diversity in cell wall lipids, particularly in the mycolic acids. Structural modification of the α-mycolic acid by introduction of cyclopropane rings as catalyzed by the methyltransferase, PcaA, is essential for a lethal, persistent infection and the cording phenotype in *M. tuberculosis*. Here, we demonstrate the presence of cyclopropanated cell wall mycolates in the nonpathogenic strain *Mycobacterium smegmatis* and identify *MSMEG_1351* as a gene encoding a PcaA homologue. Interestingly, α-mycolic acid cyclopropanation was inducible in cultures grown at 25 °C. The growth temperature modulation of the cyclopropanating activity was determined by high resolution magic angle spinning NMR analyses on whole cells. In parallel, quantitative reverse transcription-PCR analysis showed that *MSMEG_1351* gene expression is up-regulated at 25 °C compared with 37 °C. An *MSMEG_1351* knock-out strain of *M. smegmatis*, generated by recombineering, exhibited a deficiency in cyclopropanation of α-mycolates. The functional equivalence of PcaA and *MSMEG_1351* was established by cross-complementation in the *MSMEG_1351* knock-out mutant and also in a Δ*pcaA* strain of *Mycobacterium bovis* BCG. Overexpression of *MSMEG_1351* restored the wild-type mycolic acid profile and the cording phenotype in BCG. Although the biological significance of mycolic acid cyclopropanation in nonpathogenic mycobacteria remains unclear, it likely represents a mechanism of adaptation of cell wall structure and composition to cope with environmental factors.

Mycolic acids are major components of the hydrophobic cell wall of Corynebacterineae (1-4). These α-branched β-hydroxylated long chain fatty acids are covalently linked to the arabinogalactan layer that is attached to the peptidoglycan backbone and are also present as extractable lipids conjugated with sugars such as trehalose, forming trehalose dimycolate (4). Mycolic acids from mycobacteria possess a long main carbon chain called meromycolate, which in its nascent form is interrupted by double bonds at two specific sites called the proximal (closer to the β-hydroxy) and the distal positions. Chemical modifications of these double bonds give rise to different types of mycolic acids, depending on the nature of the chemical groups introduced. *Mycobacterium tuberculosis* carries the following three types of mycolic acids: α-subtypes, containing two *cis*-cyclopropane rings, and two oxygenated subtypes, harboring methoxy and keto functions on the distal position, with a *cis*- or *trans*-cyclopropane ring on the proximal site (1, 3). These chemical modifications are performed by a group of S-adenosylmethionine (AdoMet)<fnref n="3" />-dependent methyltransferases (3). These enzymes share extensive sequence similarity, but genetic studies have revealed the distinct functional characteristics of each in the biosynthesis of mycolic acids. For example, in *M. tuberculosis*, PcaA is required for *cis*-cyclopropanation at the proximal site of α-mycolates (5), whereas MmaA2 converts double bonds to *cis*-cyclopropane rings at the distal and proximal positions of α- and oxygenated mycolates, respectively (6), and CmaA2 introduces a *trans*-cyclopropane ring in oxygenated mycolates (7). MmaA4 (Hma) is required for the production of both keto and methoxy mycolates (8) and MmaA3 for the methoxy species (9). Some of these enzymes have been shown to be important for virulence (5, 8, 10, 11) and to be inhibited by (12) or required for the activation of the antitubercular drug thiacetazone (13).

<footnote>* This work was supported in part by Très Grands Equipements Résonnance Magnétique Nucléaire Très Haut Champs Fr3050.</footnote>

<footnote>§ The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1, Tables S1 and S2, and additional references.</footnote>

<footnote n="1">¹ Present address: Equipe SP2, INSERM U919, GIP-CYCERON, Campus Jules Horowitz, BP 5229, Caen, France.</footnote>

<footnote n="2">² Supported by a grant from the CNRS (Action Thématique Incitative sur Programme "Microbiologie Fondamentale"). To whom correspondence should be addressed. Tel.: 33-4-67-14-33-81; Fax: 33-4-67-14-42-86; E-mail: laurent.kremer@univ-montp2.fr.</footnote>

<footnote n="3">³ The abbreviations used are: AdoMet, S-adenosylmethionine; EI, electronic impact; HR-MAS, high resolution magic angle spinning; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MAME, mycolic acid methyl ester; *M. tuberculosis*, *Mycobacterium tuberculosis*; MS, mass spectrometry.</footnote>
## Mycolic Acid Cyclopropanation in *M. smegmatis*

The fast growing nonpathogenic *Mycobacterium smegmatis* species is characterized by a mycolic acid profile consisting mainly of *cis/cis* and *cis/trans* diethylenic α-mycolates, the mono-ethylenic shorter α' subtype, as well as the epoxy mycolates (supplemental Fig. S1) (3, 14, 15). Therefore, because of the apparent lack of cyclopropane rings, *M. smegmatis* was used in early experiments as a surrogate strain to identify and investigate the role of *M. tuberculosis* mycolic acid methyltransferases. For instance, the overexpression of *M. tuberculosis cmaA1* leads to the conversion of the distal *cis* double bond into a *cis*-cyclopropane ring in the α-mycolate of *M. smegmatis* (15). A similar strategy was used to characterize other *M. tuberculosis* methyltransferases, including CmaA2 (16) and MmaA2 (17). It is noteworthy that the heterologous overexpression studies yielded different results from those obtained in null mutants of the methyltransferase genes in *M. tuberculosis*, thus leading to conflicting interpretations of the substrate specificities of these enzymes.

Mining the *M. smegmatis* genome revealed the presence of at least seven predicted methyltransferases, from which only one, MSMEG_0913, has recently been characterized and shown to specifically add a methyl branch to the proximal site of α- and epoxy-mycolates (18). The presence of several related genes encoding potential AdoMet-dependent methyltransferases in this species suggests that *M. smegmatis* has the ability to cyclopropanate its mycolic acids, although this chemical modification may not be apparent under the standard conditions used to grow *M. smegmatis* in the laboratory. In contrast to *M. tuberculosis*, which replicates at 37 °C in the human host, *M. smegmatis* is a saprophytic species that dwells in the soil, where it is likely exposed to rapidly changing environmental conditions (19, 20). Therefore, we postulated that *M. smegmatis* utilizes this panel of methyltransferases differentially in response to environmental changes. It is well established that bacteria are able to chemically modify their phospholipids in response to environmental changes, usually by altering the acyl chains of their membrane phospholipids (21). The three main acyl chain modifications observed involve double bonds as follows: desaturation to generate an unsaturated acyl chain, *cis/trans* isomerization, and cyclopropanation where a methylene carbon is added across the double bond to form a three-membered ring. However, there are few data available regarding the capacity of *M. smegmatis* to cyclopropanate mycolic acids. In general, cyclopropanated mycolic acids are considered to be a minor component of the cell wall in this species. Some Corynebacterineae, including *M. smegmatis* (22), have also been reported to alter their mycolic acid profile in response to changes in culture conditions like growth temperature (23–27). Thus, in *M. smegmatis*, the relative amounts and chain length of the different subclasses of mycolic acids are modified according to the growth temperatures (22). Likewise, in *Mycobacterium thermoresistibile*, mycolic acid cyclopropanation has been shown to be modulated by this environmental factor (26).

Here, we show that mycolic acid cyclopropanation in *M. smegmatis* is stimulated at lower growth temperatures. In addition, we identify a previously uncharacterized gene, *MSMEG_1351*, encoding a putative methyltransferase, the expression of which is regulated by temperature. We demonstrated

that MSMEG_1351 catalyzes *cis*-cyclopropanation at the proximal site of α-mycolic acids and that this activity is significantly enhanced at temperatures lower than 37 °C. Moreover, functional complementation of a *Mycobacterium bovis* BCG Δ*pcaA* mutant with MSMEG_1351 restores both the *cis*-cyclopropanation of α-mycolates and the cording phenotype characterizing *M. bovis* BCG or *M. tuberculosis*, strongly indicating that MSMEG_1351 is a functional orthologue of PcaA.

## EXPERIMENTAL PROCEDURES

**Bacterial Strains, Media, and Growth Conditions**—Bacterial strains used in this study are summarized in supplemental Table S1. *M. smegmatis* and *M. bovis* BCG Pasteur 1173 P2 strains were routinely maintained at 37 °C in Sauton's medium containing 0.025% tyloxapol (Sigma) and supplemented with 25 µg/ml kanamycin and/or 50 µg/ml hygromycin when required. Transformed mycobacterial strains were selected on Middlebrook 7H10 agar plates with oleic acid/albumin/dextrose/catalase enrichment and the appropriate antibiotics (25 µg/ml kanamycin and/or 50 µg/ml hygromycin). When investigating growth temperature effects on mycobacteria, cultures were diluted below $A_{600} \sim 0.1$ and incubated at the indicated temperatures until $A_{600}$ reached 0.6–0.8 before harvesting the cells. For each transformation experiment, three independent clones were selected and maintained in Sauton's medium in the presence of kanamycin and hygromycin. Mycolic acid profile was verified for all three clones, and if the results were comparable, only one was retained for further analyses. *Escherichia coli* TOP10 strain was grown in Luria Broth agar supplemented with 25 µg/ml kanamycin when required.

**DNA Manipulation**—Restriction enzymes, T4 DNA ligase, and Vent DNA polymerase were purchased from New England Biolabs. Genomic DNA of *M. smegmatis* wild-type and mutagenized strains was extracted as described earlier (28). Briefly, glycine 1% (w/v) was added to 10 ml of late-log cultures that were then incubated around 6 h at 37 °C. Cells were pelleted and resuspended in 500 µl of 25 mM Tris/HCl, pH 8.0, 10 mM EDTA, 50 mM glucose, 1 mg/ml lysozyme and incubated overnight at 37 °C. Then 150 µl of a 2:1 (v/v) solution of 10% (w/v) SDS and 10 mg/ml proteinase K was added. This mixture was incubated at 55 °C for 20–40 min. Then 200 µl of 5 mM NaCl and 160 µl of 4.1% NaCl and 10% hexadecyltrimethylammonium bromide (Sigma) were added, and the mixture was incubated for 10 min at 65 °C. Lysates were then extracted twice with 24:1 (v/v) chloroform/isoamyl alcohol, and DNA was concentrated by isopropyl alcohol precipitation. Southern blot experiments were performed with the DIG High Prime DNA labeling and detection starter kit II (Roche Applied Science) according to the manufacturer's recommendations, as described previously (29).

**Construction of *M. smegmatis* ΔMSMEG_1351 Deletion Mutant**—All genetic manipulations in *M. smegmatis* were carried out using a recently developed recombineering technique in mycobacteria (30). Briefly, an allelic exchange substrate for MSMEG_1351 deletion was prepared by amplifying the left and right flanking arms and cloning them on either side of the hygromycin-resistant gene in the shuttle vector pYUB854. The left arm of each gene was cloned between AflII and XbaI and the

<figure><img src="image_3.png" /></figure>
Mycolic Acid Cyclopropanation in *M. smegmatis*

right arm between NheI and BglII. The allelic exchange sub-
strate was then released from the vector backbone by digesting
with AflII and BglII and electroporated into mc²¹⁵⁵ expressing
recombineering functions from pJV53 (30). Colonies resistant
to kanamycin and hygromycin were screened for correct gene
replacement by PCR, and selected clones were validated by
Southern blot analysis. The same strategy was followed to dis-
rupt genes *MSMEG_0902* and *MSMEG_1203*. Primers used to
amplify the left and right arms of each gene are listed in
*supplemental Table S2*.

Complementation of *M. smegmatis* Δ*MSMEG_1351*—For complementation of *M. smegmatis* Δ*MSMEG_1351*, the *MSMEG_1351* gene was cloned into vector pMV306 allowing stable integration of the cloned sequences in the mycobacterial genome. *MSMEG_1351*, including an additional 250-bp promoter-containing sequence, was amplified by PCR, using *Msm* mc²¹⁵⁵ chromosomal DNA as a template and the primers 5'-GCA TGG TGC TTC TAG ACG GGA TGG GTC-3' and 5'-CGC ATA GCG AAT TCG AAG AGC CGC TAC TTC G-3' containing XbaI and EcoRI sites, respectively (underlined). The amplified product was cloned in the XbaI and EcoRI restriction sites in the vector pMV306, thus generating pMV306_1351. In this plasmid, the *MSMEG_1351* gene is placed under the control of its own promoter-containing region. Prior to the complementation experiments, the Δ*MSEG1351* mutant was cured of the recombineering plasmid pJV53 by successive sub-culturing of the strain in liquid medium in the absence of kanamycin, followed by plating on 7H10 agar. One of the hygromycin-resistant and kanamycin-sensitive clones was isolated and used as a host for the introduction of plasmids pMV306 or pMV306_1351.

Complementation of *M. bovis* BCG Δ*pcaA* Mutant—For complementation experiments, the mc²²⁸⁰¹ (BCG Pasteur *pcaA*::Tn5370) strain was transformed either with pMV261_pcaA (12) or pMV261_1351, which was constructed as follows. The gene was amplified by PCR using *M. smegmatis* mc²¹⁵⁵ chromosomal DNA as a template and the primers 5'-TGA CCA AGC AGC CCG GAA AGC TA-3' and 5'-CGC ATA GCG AAT TCG AAG AGC CGC TAC TTC G-3' (containing an EcoRI site, underlined). The amplified product was cloned as a blunt/EcoRI fragment into the vector previously digested by MscI and EcoRI. In both pMV261_pcaA and pMV261_1351, the transgenes were placed under the control of the constitutive *hsp60* promoter.

Mycolic Acid Analyses—Lipids were metabolically radiola-
beled with 1 µCi/ml [2-¹⁴C]acetate (56 mCi/mmol, Amersham
Biosciences) and added to mid-logarithmic phase cultures for
5–7 h. Mycolic acids were extracted as described previously
(12) and analyzed by TLC on silica-coated plates. Mycolates
were resolved either by normal phase TLC in hexane/ethyl ace-
tate (19:1, v/v), run three times, or on plates impregnated with
10% silver nitrate in petroleum ether/diethyl ether (17:3, v/v),
run five times (only three times in case of mycolates from M.
bovis BCG strains). Two-dimensional TLC on silver nitrate-
impregnated plates was carried out with hexane/ethyl acetate
(19:1, v/v), run three times in the first dimension, followed by
petroleum ether/diethyl ether (17:3, v/v), run five times in the
second dimension (twice and three times for mycolates from M.

*bovis* BCG strains). TLC plates were typically exposed over-
night to Kodak Biomax MR films to reveal ¹⁴C-labeled lipids.

Purification and Structural Lipid Analysis—The spot corre-
sponding to lipid Z (missing in the ΔMSMEG_1351 mutant)
was purified by extraction and separation of total fatty acids and
mycolic acids from a 100-ml culture of the complemented
strain on 20-cm-wide preparative TLC plates. α-Mycolic acids
were recovered by scraping off the plates, extracted from the
silica with diethyl ether and resolved on 20-cm-wide silver
nitrate impregnated TLC plates. The desired spot was then sim-
ilarly recovered and extracted from the silica. Radiolabeled
mycolic acid methyl esters (MAMEs) from the ΔMSMEG_1351
mutant and the complemented strain were loaded on the edges
of the TLC plate as internal controls to unambiguously localize
the lipid of interest. The purified lipid was then subjected to a
thorough structural analysis using combination NMR and MS.

NMR Analyses—For liquid NMR, purified MAME samples were dissolved in deuterated chloroform containing 0.03% of tetramethyl silane for proton referencing and transferred into standard 5-mm tubes. Unidimensional proton experiments were recorded at 300 K on a Bruker Avance 400 spectrometer equipped with a 5-mm broad band inverse probe. For HR-MAS NMR analysis, cell pellets were washed several times with deuterium oxide to remove labile protons. HR-MAS 4-mm ZrO₂ rotors (Cortecnet, France) were filled with 50 µl of cell suspension in D₂O with 0.025% acetone (v/v) for proton referencing, centrifuged at low speed, and closed. Unidimensional proton spectrum was recorded at 293 K on a Bruker AvanceII 800 spectrometer (Bruker, Karlsruhe, Germany) equipped with a ¹H/¹³C/¹⁵N 4-mm HR-MAS probe, spinning at 8 kHz, to assess the quality of the preparation. Then 10 µl of liquid were removed, replaced by 10 µl of deuterated chloroform, and stirred before recording proton experiments. The different mutant spectra were compared after normalization of the methyl signal at 0.94 ppm.

Mass Spectrometric Analyses—Mass spectrometric analyses of intact MAMEs were performed on a Voyager Elite reflectron MALDI-TOF mass spectrometer (PerSeptive Biosystems, Framingham, MA), equipped with a 337-nm UV laser. Samples were solubilized in 1 µl of chloroform/methanol (2:1, v/v) and mixed on target with 1 µl of 2,5-dihydroxybenzoic acid matrix solution (10 mg/ml dissolved in chloroform/methanol 2:1, v/v). Electronic impact mass spectrometry (EI-MS) of MAMEs was performed on a TSQ Quantum GC (Thermo Fisher Scientific Electron) using direct insertion probe with a desorption temperature ranging from 50 to 450 °C.

**Quantitative Reverse Transcription-PCR**—Total mRNAs were extracted following the method described earlier (28), except that a bead beater apparatus was used to disrupt the bacterial cells. Briefly, cells from 5 ml of mid-logarithmic cultures were harvested, resuspended in 1 ml of RNA protect reagent (Qiagen), and incubated for 1 h on ice. The cells were collected, resuspended in 1 ml of RLT buffer from the RNeasy kit (Qiagen), transferred in a Lysing matrix B tube (MP Bio), processed in a bead beater apparatus 45 s at maximal speed three times, and held on ice before centrifugation. Supernatants (750 µl) were mixed with 525 µl of ethanol, and RNA was purified with the RNeasy kit according to the manufacturer's
Mycolic Acid Cyclopropanation in *M. smegmatis*

<figure><img src="image_4.png" /></figure>

FIGURE 1. Regulation of mycolic acid cyclopropanation by growth temperature in *M. smegmatis*. Mycobacterial cultures grown at the indicated temperatures were processed for either *in vivo* relative quantification of *cis*-cyclopropane by ¹H HR-MAS NMR (A) or for ¹⁴C-radiolabeling and extraction of mycolic acid (B and C). Mycolates were resolved on a normal TLC plate (B, left panel), a silver nitrate-impregnated TLC plate (B, right panel), or by two-dimensional TLC (C). *FAME*, fatty acid methyl ester. The new spot accumulating at low growth temperatures, termed lipid Z in *B* is indicated by an arrow. α₁ and α₂ correspond to the *cis/cis* and *cis/trans* di-unsaturated α-mycolic acids, respectively. *e*, epoxy mycolic acids.

instructions. Contaminating DNA was removed following DNase I treatment (Invitrogen). RNA integrity was analyzed on a BioAnalyzer 2100 machine from Agilent, using RNA nano series II chips. Double-stranded cDNA was produced using the Superscript II or III reverse transcriptase (Invitrogen). Quantitative PCR were performed using an in-house SYBR Green mixture in a light cycler instrument (Roche Applied Science), as described previously (31). The PCR program consisted of initial denaturation at 98 °C for 3 min, 45 cycles of 98 °C for 5 s, 68 °C for 10 s, and 72 °C for 10 s. The *mysA* gene (*MSMEG_2758*), encoding a σ-factor was used as an internal standard and was amplified using the primers 5'-GAA GAC ACC GAC CTG GAA CT-3' and 5'-GAC TCT TCC TCG TCC CAC AC-3'. The *MSMEG_1351* gene was amplified using the primers 5'-AGG TTC ATC GTC ACC GAG AT-3' and 5'-TAG ACC TCC TGC GAC TGG AT-3'. Primer efficiencies, measured as described previously (31), were between 1.8 and 1.9.

*Cording Assay*—Cord reading agar was prepared as described previously (32, 33), except that Triton WR1339 was replaced by Triton X-100. Briefly, Triton X-100 was added to 7H10 medium enriched with oleic acid/albumin/dextrose/catalase and required antibiotics. Approximately 100 colony-forming units were plated, incubated at 37 °C, and visualized under a microscope MVX10 (Olympus) at ×100 magnification.

RESULTS

Cyclopropanation of Mycolic Acids Is Temperature-regulated in *M. smegmatis*—The cyclopropanation of mycolic acids in *M. smegmatis* mc2155 and its likely regulation by growth temperature were examined. The recently developed quantitative method of HR-MAS NMR (12) was used for the determination of the relative levels of mycolate cyclopropanation in intact cells of *M. smegmatis*. This method is based on the relative quantification of Ha protons of cyclopropane groups at δ −0.34 on ¹H HR-MAS NMR spectra. We applied this method to directly observe and assess the content of *cis*-cyclopropane rings in *M. smegmatis* grown at different temperatures. As shown in Fig. 1A, *cis*-cyclopropane signals detected by ¹H HR-MAS NMR increased gradually as an inverse function of the temperature, suggesting that lipid cyclopropanation is regulated by growth temperature in *M. smegmatis*. Indeed, differential integration of cyclopropane ¹H NMR signals demonstrated that the total cyclopropane content increased by 150% in cells grown at 25 °C, compared with those grown at 42 °C.

Cyclopropanation of mycolates was assessed in *M. smegmatis* grown at different temperatures and subsequently metabolically labeled with [¹⁴C]acetate. Mycolic acids were extracted and analyzed by TLC using different solvent systems. A striking difference in the ratio of the *α*-, *α'*-, and epoxy-mycolate sub-

<figure><img src="image_5.png" /></figure>
## Mycolic Acid Cyclopropanation in *M. smegmatis*

classes was observed at different temperatures (Fig. 1B, left panel). In particular, at 25 °C, the synthesis of α'-mycolates was almost completely abrogated, whereas a marked increase in the synthesis of epoxy-mycolates was observed at the lowest temperatures, consistent with the previous findings (22). Unexpectedly, when the same samples were separated on silver nitrate-impregnated TLC plates, we observed the presence of an additional band (referred to as lipid Z) appearing essentially at temperatures lower than 37 °C (Fig. 1B, right panel). Because silver nitrate retards migration of unsaturated lipids relative to cyclopropanated lipids, these results suggested that a new cyclopropanated lipid was produced during growth at low temperatures. Resolution on two-dimensional argumentation TLC suggested that the radiolabeled spot accumulating at 25 °C corresponded to cyclopropanated mycolates belonging to the α-mycolate subclass (Fig. 1C). These data support the conclusion that cyclopropanation occurs in *M. smegmatis* and are strongly enhanced at growth temperatures below 37 °C.

**MSMEG_1351** *Mutant Fails to Produce the Lipid Accumulating at Low Temperature*—An in silico search for genes encoding mycolic acid methyltransferases in *M. smegmatis* mc2155 revealed the presence of at least seven putative coding regions (18). These seven open reading frames are localized to five different loci (Fig. 2A) and share 50–70% identity (Fig. 2B). Two of these, annotated **MSMEG_1351** and **MSMEG_1350**, are present in the *mmaA1–mmaA*-containing region, although one, **MSMEG_0913**, is in the *umaA1–pcaA* region. In addition, *M. smegmatis* has four additional paralogues designated **MSMEG_1205**, **MSMEG_1203**, **MSMEG_3538**, and **MSMEG_0902**. The regions corresponding to *cmaA1* and *cmaA2* in *M. tuberculosis* are not found in *M. smegmatis*.

To validate *M. smegmatis* cyclopropanation activity, we generated *M. smegmatis* mutants in genes encoding putative methyltransferases by introducing a hygromycin resistance cassette into three differ-

ent genes located within different loci (*MSMEG_1351*, *MSMEG_1203*, and *MSMEG_0902*) to generate independent, single mutant strains. Disruption of the open reading frames in

A

*M. tuberculosis*

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

*M. smegmatis*

<figure><img src="image_8.png" /></figure>

B

<figure><img src="image_9.png" /></figure>

C

<figure><img src="image_10.png" /></figure>

D

<figure><img src="image_11.png" /></figure>
Mycolic Acid Cyclopropanation in *M. smegmatis*

each strain was confirmed by PCR analysis (data not shown) as well as by Southern blotting using a hygromycin probe (supplemental Fig. S2). Growth temperature-dependent cyclopropanation of cell wall mycolic acids in the three mutant strains was evaluated. Cultures were incubated either at 25 or 37 °C and labeled with [¹⁴C]acetate followed by mycolic acid analysis by two-dimensional TLC. There were no significant differences in mycolate profiles of the *MSMEG_0902* or *MSMEG_1203*-deficient strains (supplemental Fig. S3). In contrast, as shown in Fig. 2C, the cyclopropanated lipid Z that accumulated at 25 °C in the parental strain was hardly detectable in the *ΔMSMEG_1351* mutant strain. Except for this particular band, both parental and mutant strains exhibited a comparable mycolic acid profile. The absence of lipid Z in *ΔMSMEG_1351* mutant affected neither the growth (supplemental Fig. S4) nor the colony morphology of the mutant (data not shown). Importantly, complementation with a plasmid-borne copy of the corresponding gene fully restored the production of this lipid. Interestingly, lipid Z reproducibly accumulated at higher amounts in the complemented strain compared with the parental strain (Fig. 2C). In the complementation construct, the *MSMEG_1351* gene was placed under the control of its own promoter region, a 250-bp segment that may contain regulatory signals that allow expression to be induced at low temperatures. Restoration of the parental profile also ruled out any possible polar effect due to the introduction of the hygromycin cassette in the *MSMEG_1351* locus. Taken together, these studies identify *MSMEG_1351* as a gene necessary for the production of a cyclopropanated α-mycolate species that is synthesized at low temperature.

*MSMEG_1351 Expression Is Regulated by Growth Temperature*—Because the appearance of the cyclopropanated lipid Z was dependent on both the growth temperature and the presence of *MSMEG_1351*, we hypothesized that *MSMEG_1351* gene expression is regulated by temperature. The transcript levels of *MSMEG_1351* were estimated by quantitative PCR in *M. smegmatis* mc²155 grown at 25, 30, and 37 °C. Results presented in Fig. 2D clearly show a significant 2-fold up-regulation of the *MSMEG_1351* mRNA in four independent experiments at 25 °C compared with 37 °C, when using the *mysA* gene (*MSMEG_2758*) as an internal standard. Similar results were obtained using *rpsL* as an internal control (data not shown). These data confirm that *MSMEG_1351* is a thermally regulated gene and are in agreement with the synthesis of lipid Z at this temperature.

*Structure of the MSMEG_1351-dependent Mycolic Acid*— Cultures of the complemented strain grown at 25 °C were considered a good source of lipid Z, as it is produced in higher amounts in this strain compared with the mutant or parental strains (Fig. 2C). The extracted mycolic acids were purified as

<caption>**TABLE 1**
Identification and quantification of functional groups from lipid Z</caption>

δ indicates ¹H NMR chemical shifts of indicative protons; ¹H int. indicates integrations of ¹H signals, and RQ indicates relative quantitation of functional groups.

<table><thead><tr><th>Grps</th><th>δ (ppm)</th><th>¹H Int.</th><th>RQ</th></tr></thead><tbody><tr><td></td><td>-0.34</td><td>1.11</td><td>1.11</td></tr><tr><td></td><td>5.23</td><td>1.62</td><td>0.81</td></tr><tr><td></td><td>5.35</td><td>0.02</td><td>0.01</td></tr><tr><td>COOCH<sub>3</sub></td><td>3.71</td><td>3.00</td><td>1.00</td></tr></tbody></table>

described under “Experimental Procedures” and subjected to a detailed structural analysis. First, functional groups corresponding to mycolates were identified by ¹H NMR based on assignments of characteristic protons from *trans*-ethylenic groups (5.23 ppm), *cis*-ethylenic groups (5.35 ppm), carboxymethyl groups (3.71 ppm), and *cis*-cyclopropane groups (−0.34 ppm) (Table 1), in agreement with previously published parameters (12). Integration of individual ¹H signals normalized on the −COOCH₃ signal indicated an average of 1.11 *cis*-cyclopropane group and 0.81 *trans*-ethylenic group per molecule (Table 1), thus strongly suggesting that the purified mycolate is a mono-cyclopropanated α-type mycolate. No *trans*-cyclopropanes could be observed on the same spectrum. Furthermore, MALDI-TOF MS analysis of lipid Z showed two [M + Na]⁺ major signals at *m/z* 1174 and 1202, indicative of the presence of a family of C₇₈ and C₈₀ α-mycolic acids (Fig. 3A, lower panel) (34). By comparison, the α-mycolates devoid of lipid Z from *M. smegmatis* grown at 25 °C, as well as total α-mycolates purified from *M. smegmatis* grown at 42 °C (data not shown), exhibited a more complex pattern dominated by two major peaks at *m/z* 1160 and 1188, indicative of the presence of two major C₇₇ and C₇₉ α-mycolic acid subtypes (Fig. 3A, upper panel), as established previously in *M. smegmatis* (18). Comparison of high and low mobility α-mycolates on silver-impregnated TLC established that lipid Z was substituted on average by an additional −CH₂− group, in accordance with the observation in NMR of a

**FIGURE 2.** **Identification of the genes involved in the production of the cyclopropanated mycolates.** A, schematic representation and genomic organization of the potential methyltransferases in *M. smegmatis* and comparison with *M. tuberculosis*. Black boxes indicate the mycolic acid methyltransferases; gray boxes indicate open reading frames encoding conserved proteins between the two species, and white boxes represent open reading frames unique to either *M. smegmatis* or *M. tuberculosis*. Coordinates of each gene cluster are indicated in kb. B, alignment of the *M. smegmatis* putative methyltransferases. The AdoMet-binding site as described previously (14) is underlined. C, argentation TLC of ¹⁴C-radiolabeled mycolic acids from the parental strain (1st lane), the Δ*MSMEG_1351* mutant carrying either the empty pMV306 (2nd lane) or pMV306_1351 (3rd lane), all grown at 25 °C. The arrowhead indicates the position of lipid Z that is lacking in the Δ*MSMEG_1351* mutant. D, temperature-regulated expression of *MSMEG_1351*. Wild-type *M. smegmatis* was grown at the indicated temperature, and the levels of *MSMEG_1351* transcripts relative to those of the RNA polymerase α-factor *mysA* gene (*MSMEG_2758*) were measured by quantitative reverse transcription-PCR. *MSMEG_1351* transcript levels at the different temperatures were normalized to those from cells growing at 37 °C. Results are expressed as means ± S.D. from four independent experiments.

<figure><img src="image_12.png" /></figure>
Mycolic Acid Cyclopropanation in M. smegmatis

<figure><img src="image_13.png" /></figure>

<figure><img src="image_14.png" /></figure>

<figure><img src="image_15.png" /><figcaption>FIGURE 3. Structural analysis of lipid Z. A, MALDI-MS analysis of intact carboxymethylated mycolic acids from α-mycolic acids devoid of lipid Z (upper panel) and lipid Z (lower panel). B, EI-MS analysis of in-source pyrolysis fragment generated from a mixture of α-mycolates lacking lipid Z (upper panel) or containing lipid Z (lower panel). C, EI-MS analysis of fragment ions generated from carboxymethylated lipid Z. Cis- and trans-conformation of functional groups were omitted in schematic representations of mycolates for the sake of clarity.</figcaption></figure>

<figure><img src="image_16.png" /></figure>

<figure><img src="image_17.png" /></figure>

<figure><img src="image_18.png" /></figure>

single *cis*-cyclopropane group per mycolate. Next, the location of the cyclopropane group on the meromycolyl chain was investigated by in-source pyrolysis of purified α-mycolates and analysis in electronic impact-mass spectrometry (EI-MS) (Fig. 3B). Indeed, the 14 mass unit increment observed by MALDI-MS on intact molecules was associated with a family of [M + H]⁺ signals at *m/z* 755/783 in α-mycolates devoid of lipid Z and to a family of signals at *m/z* 769/797 in lipid Z assigned to the meromycolyl chain of noncyclopropanated and mono-cyclopropanated α-mycolates, respectively. Accordingly, pyrolysis of both α-mycolates also generated a [M + H]⁺ signal at *m/z* 382 attributed to the fatty C₂₄ acid chain, including the carboxyl group (data not shown). Finally, EI-MS analysis of intact lipid Z generated an intense primary fragment ion at *m/z* 648, originating from the cleavage of meromycolyl chain next to the cyclopropane group (Fig. 3C) (35). This fragment is further degraded by recurrent fragmentation of the fatty acyl chain of the α-mycolate that eventually generates a secondary fragment presenting a residual C₃ fatty acid chain observed at *m/z* 367.2. Taken together, the data from NMR, MALDI-MS, and EI-MS establish that lipid Z is a mono-unsaturated, mono-cyclopropanated α-mycolate and strongly suggest that the *cis*-cyclopropane ring is located at the proximal position in the meromycolyl chain.

MSMEG_1351 Can Replace pcaA in M. bovis BCG—The above structural analyses of lipid Z suggest that MSMEG_1351

is a methyltransferase involved in *cis*-cyclopropanation of the proximal double bond in α-mycolates. In *M. tuberculosis* or *M. bovis* BCG, PcaA is required for the introduction of the proximal *cis*-cyclopropane ring of the α-mycolates (5). Therefore, we investigated whether MSMEG_1351 and PcaA are functionally equivalent by complementing *M. bovis* BCG mc²2801 (BCG Pasteur pcaA::Tn5370) with *MSMEG_1351*, placed either under the control of its own promoter (pMV306_1351) or the constitutive *hsp60* promoter (pMV261_1351). As shown in Fig. 4, A and B, *M. bovis* BCG mc²2801 presented an altered α-mycolic acid profile as reported earlier (5), which could be restored by complementation through overexpression of *pcaA*. A similar mycolate profile was observed following overexpression of *MSMEG_1351* in *M. bovis* BCG mc²2801 via the constitutively strong promoter *hsp60*. When expressed from its native promoter, lower but reproducible levels of *cis*-cyclopropanated α-mycolic acids were obtained, which can be attributed to the fact that *M. bovis* BCG mc²2801 was grown at 37 °C, a temperature where *MSMEG_1351* gene expression is only mildly induced (Fig. 2D). Similarly, overexpression of *pcaA* in the Δ*MSMEG_1351* mutant fully restored the production of the cyclopropanated α-mycolic acid lacking in this mutant (Fig. 4D). We conclude from these results that MSMEG_1351 and PcaA are functionally equivalent.
Mycolic Acid Cyclopropanation in *M. smegmatis*

<figure><img src="image_19.png" /><figcaption>B</figcaption></figure>

<figure><img src="image_20.png" /><figcaption>C</figcaption></figure>

<figure><img src="image_21.png" /><figcaption>D</figcaption></figure>

<figure><img src="image_22.png" /></figure>

FIGURE 4. **Complementation of *M. bovis* BCG Δ*pcaA* *M. smegmatis* ΔMSMEG_1351** mutants. Complementation of *M. bovis* BCG Δ*pcaA* by MSMEG_1351. One-dimensional (A) and two-dimensional (B) argentation TLC of ¹⁴C-radiolabeled mycolic acids from *M. bovis* BCG Pasteur and BCG mc²2801 (BCG Pasteur pcaA::Tn5370) transformed with various vectors and grown at 37 °C. The arrowhead indicates the position of the hybrid mycolate accumulating in the Δ*pcaA* mutant, with a *cis* double bond at the proximal position in place of a *cis*-cyclopropane present in the wild-type α-mycolate as determined previously (5). α, α-mycolates; *K*, keto-mycolates; *WT*, wild type. C, single BCG colonies grown on cord reading agar and photographed after 15 days of incubation at 37 °C. Magnification, ×100. D, complementation of *M. smegmatis* ΔMSMEG_1351 by *pcaA*. Two-dimensional TLC analysis of ¹⁴C-radiolabeled mycolic acids from *M. smegmatis* ΔMSMEG_1351 transformed either with pMV261, pMV306_1351, or pMV261_pcaA grown at 25 °C. Arrows indicate the position of the cyclopropanated mycolate missing in the ΔMSMEG_1351 mutant.

MSMEG_1351 Restores the Cording Phenotype of BCG ΔpcaA—BCG ΔpcaA mutant was first recognized for its defect in cord formation (5). This prompted us to investigate if MSMEG_1351 could also replace pcaA for the cording phenotype in BCG. As shown in Fig. 4C, transformation of *M. bovis* BCG mc²2801 with MSMEG_1351 restored the ability to form the characteristic long serpentine cords.

DISCUSSION

Cyclopropanation is a well studied structural modification of
mycolic acids typically seen in slow growing pathogenic mycobac-
teria. In contrast, fast growing species produce large amounts of
unsaturated mycolic acids (14, 15, 36). In a recent study, Laval et al.
(18) demonstrated the presence of cyclopropanated mycolates in
the fast growing M. smegmatis by characterization of the methyl-
transferase MSMEG_0913 (UmaA1). It was demonstrated that a
MSMEG_0913 deletion mutant no longer synthesized mycolates

containing a methyl branch adjacent to either a *trans*-cyclopropyl
group or a *trans* double bond at the proximal position of both
α- and epoxy-mycolates. Surprisingly, complementation of this
mutant with the putative *M. tuberculosis* mycolic acid methyl-
transferase UmaA1 did not restore the wild-type phenotype, indi-
cating that *umaA1* and *MSMEG_0913* are not functionally
orthologous, despite their synteny and high similarity (18).
This study clearly indicates that MSMEG_1351 and PcaA
(sharing 67% amino acid identity) are functionally ortholo-
gous, as *MSMEG_1351* could complement a BCG Δ*pcaA*
mutant and, conversely, *pcaA* restored a wild-type mycolic
acid profile in the *M. smegmatis* ΔMSMEG_1351 mutant.

This study not only confirms the presence of cyclopropana-
tion in *M. smegmatis* but also highlights the ability of this
species to regulate cyclopropanation according to growth tem-
perature. It is very likely that the inherent capacity of cyclopro-
panation has been overlooked in many earlier studies because

<figure><img src="image_23.png" /></figure>
Mycolic Acid Cyclopropanation in M. smegmatis

of culturing *M. smegmatis* at 37 °C, where cyclopropanation is virtually absent. Here, we provide compelling evidence that *M. smegmatis* has a propensity to introduce cyclopropane rings in α-mycolates at growth temperatures below 37 °C and that this activity is catalyzed by MSMEG_1351. Inactivation of this gene in *M. smegmatis* abolished the production of cyclopropanated α-mycolates that accumulate at low temperatures, a phenotype that was reversed following complementation of the mutant with a functional MSMEG_1351 gene.

PcaA has been shown to be required for the cording phenotype in the tubercle bacillus and for its long term persistence in mice (5) and is thought to be absent in *M. smegmatis*. Only one gene, *MSMEG_0913*, is present in the genomic region of *M. smegmatis* that is "equivalent" to the *umaA1-pcaA* gene cluster in *M. tuberculosis* (Fig. 2A), and it has been assigned a clear function, distinct from the one catalyzed by PcaA (18). In *M. tuberculosis*, inactivation of *pcaA* is responsible for virulence attenuation, while stimulating a less severe granulomatous pathology in the mouse model (5). This was further validated by demonstrating that purified trehalose dimycolate from the Δ*pcaA* strain was hypo-inflammatory for macrophages (11). The presence of persistent bacteria is considered to be the major reason for a lengthy therapy (37). Therefore, genes such as *pcaA* have been proposed to be attractive targets for the development of drugs against persistent bacilli (5, 38). The determination of the crystal structure of PcaA has provided a foundation for rational drug design for the development of new inhibitors effective against persistent bacteria (39). Interestingly, subsequent work demonstrated that PcaA, along with other cyclopropane mycolic acid synthases, was extremely sensitive to inhibition by thiacetazone, a second line antitubercular drug (12). Another molecule dioctylamine, acts as a substrate mimic and inhibits the function of multiple cyclopropane mycolic acid synthases, including PcaA, resulting in loss of cyclopropanation, cell death, loss of acid fastness, and synergistic killing with isoniazid and ciprofloxacin (40).

The occurrence of an orthologue of a pathogenicity gene, *pcaA*, in a saprophytic species is rather intriguing. Although virulence factors typical of pathogenic species are thought to be absent or inactivated in nonpathogenic strains, this deserves to be re-examined. Our study revealed that expression of *MSMEG_1351* was low at 37 °C, based on quantitative reverse transcription-PCR analysis as well as by the apparent lack of cyclopropanated α-mycolates. However, relative amounts of *MSMEG_1351*-specific transcripts increased significantly at lower growth temperatures, and this correlated with the accumulation of *cis*-cyclopropane rings, as indicated by biochemical and structural analyses and also directly on whole cells by HR-MAS NMR. However, in contrast to *pknG* (a virulence gene mediating intracellular survival of *M. tuberculosis*), which is not translated in *M. smegmatis* (41), expression of *pcaA* (*MSMEG_1351*) was temperature-dependent, and further work will be required to identify the regulatory region(s) upstream of *MSMEG_1351*. These results indicate that the pathogenicity-associated *pcaA* gene is differentially expressed in pathogenic and nonpathogenic mycobacteria.

The mycobacterial cell wall has a variable composition allowing the bacteria to maintain a constant viscosity in the face of

changing environmental conditions (42, 43). Several mycobacterial species, including *M. smegmatis* (22, 24, 26), have been shown to respond to changing growth temperatures by adjusting the proportion of lipids found in the *trans*-configuration. These alterations in lipid structure are not in the plasma membrane lipids but rather in the mycolic acids, as would be expected because the cell wall represents the major permeability barrier in the mycobacteria. In *M. smegmatis*, this alteration results in changes in the geometry of the major olefinic mycolic acids, and in slow growing species, such as *Mycobacterium avium*, this alteration occurs through changes in the geometry about cyclopropane rings within the longer meromycolate chain. This alteration has been shown to directly correlate with changes in cell wall permeability to lipophilic agents (44). We therefore investigated whether proximal cyclopropanation alters cell wall permeability by testing the effect of various drugs, including rifampicin, isoniazid, erythromycin, and crystal violet, in the wild-type, the mutant, and the complemented strains. Comparable minimal inhibitory concentrations were obtained regardless of the strain (data not shown), suggesting that the loss or the gain of proximal cyclopropanation does not influence susceptibility to these drugs and cell wall permeability.

Because free mycolates have been shown to be important components of mycobacterial biofilms (45), and because *M. smegmatis* biofilms are formed at 30 °C (46), a temperature that is permissive to proximal cyclopropanation, we investigated whether proximal cyclopropanation affects biofilm formation. However, we did not observe any biofilm defect with the Δ*MSMEG_1351* strain (data not shown).

The biological significance of mycolic acid cyclopropanation of saprophytic mycobacteria is currently not known, although one can envisage that it represents a mechanism allowing these species to cope with environmental factors and that cyclopropanation occurs when growing in their natural habitats. In contrast to *M. tuberculosis*, which is not exposed to temperature variations during infection in a human host, saprophytic mycobacteria have to face various environmental and temperature changes. *M. smegmatis* is present in genital secretions (smegma) and is also found in the soil, dust, and water. The presence of a large family of methyltransferase-encoding genes in the annotated genome indicates the possible requirement of these enzymes in adaptation to various habitats. Hence, ascribing a role to the proximal cyclopropanation of mycolates in thermal adaptation in *M. smegmatis* is an attractive hypothesis that requires further attention. Although the *MSMEG_0902* and *MSMEG_1203* mutants did not exhibit altered mycolic acid profiles compared with the parent stain, neither at 25 nor at 37 °C (supplemental Fig. S3), it remains possible that these genes (along with *MSMEG_1350*, *MSMEG_1205*, and *MSMEG_3538*) participate in other modifications of the mycolyl chain that are apparent only under certain environmental conditions. Assignment of specific functions to these enzymes awaits further genetic and physiological studies. In this context, the noninvasive technique of HR-MAS NMR could be invaluable for estimating the levels of *cis*-cyclopropanes in intact whole cell basis. Finally, although *M. smegmatis* was used here as the prototype of nonpathogenic rapid growers,

<figure><img src="image_24.png" /></figure>
it is tempting to speculate that other nonpathogenic species
have the capacity to cyclopropanate their mycolates.

Acknowledgments—We thank W. R. Jacobs and M. Glickman for the kind gift of BCG mc²2801. We also thank Christophe Biot for help in structural analyses and Benedicte Gauriat-Deroy from Thermo Fisher Scientific Electron for EI analyses of pyrolysis fragments. The 800 MHz NMR spectrometer was funded by European Union (FEDER), Ministère Français de l'Enseignement Supérieur et de la Recherche, Région Nord-Pas de Calais, Université Lille1-Sciences et Technologies, and CNRS.

REFERENCES

1. Brennan, P. J., and Nikaido, H. (1995) *Annu. Rev. Biochem.* **64**, 29–63

2. Takayama, K., Wang, C., and Besra, G. S. (2005) *Clin. Microbiol. Rev.* **18**, 81–101

3. Kremer, L., Baulard, A. R., and Besra, G. S. (2000) in *Mycobacteria* (Hatfull, G. F., and Jacobs, W. R., Jr., eds) pp. 173–190, American Society for Microbiology, Washington, D. C.

4. Daffé, M., and Draper, P. (1998) *Adv. Microb. Physiol.* **39**, 131–203

5. Glickman, M. S., Cox, J. S., and Jacobs, W. R., Jr. (2000) *Mol. Cell* **5**, 717–727

6. Glickman, M. S. (2003) *J. Biol. Chem.* **278**, 7844–7849

7. Glickman, M. S., Cahill, S. M., and Jacobs, W. R., Jr. (2001) *J. Biol. Chem.* **276**, 2228–2233

8. Dubnau, E., Chan, J., Raynaud, C., Mohan, V. P., Lanéelle, M. A., Yu, K., Quémard, A., Smith, I., and Daffé, M. (2000) *Mol. Microbiol.* **36**, 630–637

9. Behr, M. A., Schroeder, B. G., Brinkman, J. N., Slayden, R. A., and Barry, C. E., 3rd (2000) *J. Bacteriol.* **182**, 3394–3399

10. Dao, D. N., Sweeney, K., Hsu, T., Gurcha, S. S., Nascimento, I. P., Roshevsky, D., Besra, G. S., Chan, J., Porcelli, S. A., and Jacobs, W. R. (2008) *PLoS Pathog.* **4**, e1000081

11. Rao, V., Fujiwara, N., Porcelli, S. A., and Glickman, M. S. (2005) *J. Exp. Med.* **201**, 535–543

12. Alahari, A., Trivelli, X., Guérardel, Y., Dover, L. G., Besra, G. S., Sacchet-tini, J. C., Reynolds, R. C., Coxon, G. D., and Kremer, L. (2007) *PLoS ONE* **2**, e1343

13. Alahari, A., Alibaud, L., Trivelli, X., Gupta, R., Lamichhane, G., Reynolds, R. C., Bishai, W. R., Guérardel, Y., and Kremer, L. (2009) *Mol. Microbiol.* **71**, 1263–1277

14. Barry, C. E., 3rd, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., and Yuan, Y. (1998) *Prog. Lipid Res.* **37**, 143–179

15. Yuan, Y., Lee, R. E., Besra, G. S., Belisle, J. T., and Barry, C. E., 3rd. (1995) *Proc. Natl. Acad. Sci. U.S.A.* **92**, 6630–6634

16. George, K. M., Yuan, Y., Sherman, D. R., and Barry, C. E., 3rd. (1995) *J. Biol. Chem.* **270**, 27292–27298

17. Yuan, Y., and Barry, C. E., 3rd (1996) *Proc. Natl. Acad. Sci. U.S.A.* **93**, 12828–12833

18. Laval, F., Haites, R., Movahedzadeh, F., Lemassu, A., Wong, C. Y., Stoker, N., Billman-Jacobe, H., and Daffé, M. (2008) *J. Biol. Chem.* **283**, 1419–1427

19. Iivanainen, E., Martikainen, P. J., Väänänen, P., and Katila, M. L. (1999) *J. Appl. Microbiol.* **86**, 673–681

20. Rao, M., Streur, T. L., Aldwell, F. E., and Cook, G. M. (2001) *Microbiology* **147**, 1017–1024

21. Cronan, J. E., Jr. (2002) *Curr. Opin. Microbiol.* **5**, 202–205

22. Baba, T., Kaneda, K., Kusunose, E., Kusunose, M., and Yano, I. (1989) *J. Biochem.* **106**, 81–86

23. Tomiyasu, I. (1982) *J. Bacteriol.* **151**, 828–837

24. Toriyama, S., Yano, I., Masui, M., Kusunose, M., and Kusunose, E. (1978) *FEBS Lett.* **95**, 111–115

25. Toriyama, S., Yano, I., Masui, M., Kusunose, E., Kusunose, M., and Aki-mori, N. (1980) *J Biochem.* **88**, 211–221

26. Kremer, L., Guérardel, Y., Gurcha, S. S., Locht, C., and Besra, G. S. (2002) *Microbiology* **148**, 3145–3154

27. Stratton, H. M., Brooks, P. R., Carr, E. L., and Seviour, R. J. (2003) *Syst. Appl. Microbiol.* **26**, 165–171

28. Larsen, M. H., Biermann, K., Tandberg, S., Hsu, T., and Jacobs, W. R., Jr. (2007) *Curr. Protoc. Microbiol.* **10A.2**, 1–21

29. Kremer, L., Gurcha, S. S., Bifani, P., Hitchen, P. G., Baulard, A., Morris, H. R., Dell, A., Brennan, P. J., and Besra, G. S. (2002) *Biochem. J.* **363**, 437–447

30. van Kessel, J. C., and Hatfull, G. F. (2007) *Nat. Methods* **4**, 147–152

31. Lutfalla, G., and Uze, G. (2006) *Methods Enzymol.* **410**, 386–400

32. Lorian, V. (1966) *Appl. Microbiol.* **14**, 603–607

33. Lorian, V. (1969) *Appl. Microbiol.* **17**, 559–562

34. Laval, F., Lanéelle, M. A., Déon, C., Monsarrat, B., and Daffé, M. (2001) *Anal. Chem.* **73**, 4537–4544

35. Minnikin, D. E. (1972) *Lipids* **7**, 398–403

36. Bhowruth, V., Alderwick, L. J., Brown, A. K., Bhatt, A., and Besra, G. S. (2008) *Biochem. Soc. Trans.* **36**, 555–565

37. Mitchison, D. A. (2004) *Front. Biosci.* **9**, 1059–1072

38. Zhang, Y., Post-Martens, K., and Denkin, S. (2006) *Drug Discov. Today* **11**, 21–27

39. Huang, C. C., Smith, C. V., Glickman, M. S., Jacobs, W. R., Jr., and Sacchettini, J. C. (2002) *J. Biol. Chem.* **277**, 11559–11569

40. Barkan, D., Liu, Z., Sacchettini, J. C., and Glickman, M. S. (2009) *Chem. Biol.* **16**, 499–509

41. Houben, E. N., Walburger, A., Ferrari, G., Nguyen, L., Thompson, C. J., Miess, C., Vogel, G., Mueller, B., and Pieters, J. (2009) *Mol. Microbiol.* **72**, 41–52

42. Barry, C. E., 3rd, and Mdluli, K. (1996) *Trends Microbiol.* **4**, 275–281

43. Sinensky, M. (1974) *Proc. Natl. Acad. Sci. U.S.A.* **71**, 522–525

44. Liu, J., Barry, C. E., 3rd, Besra, G. S., and Nikaido, H. (1996) *J. Biol. Chem.* **271**, 29545–29551

45. Ojha, A. K., Baughn, A. D., Sambandan, D., Hsu, T., Trivelli, X., Guérardel, Y., Alahari, A., Kremer, L., Jacobs, W. R., Jr., and Hatfull, G. F. (2008) *Mol. Microbiol.* **69**, 164–174

46. Ojha, A., Anand, M., Bhatt, A., Kremer, L., Jacobs, W. R., Jr., and Hatfull, G. F. (2005) *Cell* **123**, 861–873

<figure><img src="image_25.png" /></figure>